Johnson & Johnson's (JNJ.US) Nivolumab Injection is proposed to be included in the priority review

On November 12, the CDE's website announced that Johnson & Johnson's (JNJ.US) Nipocalimab injection was proposed to be included in the priority review, which is indicated for the treatment of adult and adolescent patients (aged 12 and above) with generalized myasthenia gravis (gMG) who test positive for autoantibodies. Nipocalimab is an FcRn antibody developed by Johnson & Johnson through the acquisition of Momenta Pharmaceuticals for approximately $6.5 billion. The drug has already been submitted for approval in the US in August this year for myasthenia gravis. This time being included in the proposed priority review by the CDE means it is also expected to be approved in China soon.